Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement

Stock Track

Jul 29

Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin manufacturing process.

The biopharmaceutical giant revealed plans to undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using the Horizon 2 process, a technology that enables greater immunoglobulin production. CSL also stated it intends to seek regulatory approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with clinical activities expected to commence in mid-2027.

The Horizon 2 process represents a significant advancement in plasma manufacturing efficiency, potentially allowing CSL to produce more immunoglobulin therapies from the same volume of plasma. Investors reacted positively to the news, viewing the enhanced manufacturing capability as a potential driver for improved margins and expanded treatment access in the company's core plasma therapies business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1137947072"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137947072\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137947072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137947072","market":"nz","top_or_hot":-1,"title":"Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement","media":"Stock Track","content":"<p>Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin manufacturing process.</p><p>The biopharmaceutical giant revealed plans to undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using the Horizon 2 process, a technology that enables greater immunoglobulin production. CSL also stated it intends to seek regulatory approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with clinical activities expected to commence in mid-2027.</p><p>The Horizon 2 process represents a significant advancement in plasma manufacturing efficiency, potentially allowing CSL to produce more immunoglobulin therapies from the same volume of plasma. Investors reacted positively to the news, viewing the enhanced manufacturing capability as a potential driver for improved margins and expanded treatment access in the company's core plasma therapies business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CSL Soars 5% Intraday on Horizon 2 Clinical Trials Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-29 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin manufacturing process.</p><p>The biopharmaceutical giant revealed plans to undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using the Horizon 2 process, a technology that enables greater immunoglobulin production. CSL also stated it intends to seek regulatory approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with clinical activities expected to commence in mid-2027.</p><p>The Horizon 2 process represents a significant advancement in plasma manufacturing efficiency, potentially allowing CSL to produce more immunoglobulin therapies from the same volume of plasma. Investors reacted positively to the news, viewing the enhanced manufacturing capability as a potential driver for improved margins and expanded treatment access in the company's core plasma therapies business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL.AU","symbol_name":"CSL LIMITED","start_time":0,"source_url":"","article_id":"1137947072","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137947072","pubTimestamp":1785284061,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL.AU":"CSL LIMITED"},"translate_title":"股票跟踪 | Horizon 2 临床试验公告 CSL 盘中飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1},"content_text":"Shares of CSL Limited surged 5.00% during intraday trading on Wednesday, following the company's announcement that it will launch clinical trials for its next-generation Horizon 2 immunoglobulin manufacturing process.The biopharmaceutical giant revealed plans to undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using the Horizon 2 process, a technology that enables greater immunoglobulin production. CSL also stated it intends to seek regulatory approval from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), with clinical activities expected to commence in mid-2027.The Horizon 2 process represents a significant advancement in plasma manufacturing efficiency, potentially allowing CSL to produce more immunoglobulin therapies from the same volume of plasma. Investors reacted positively to the news, viewing the enhanced manufacturing capability as a potential driver for improved margins and expanded treatment access in the company's core plasma therapies business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}